title: HIV-1 reverse transcriptase artificially targeted for proteasomal degradation induces a mixed Th1/Th2-type immune response.
abstract: Targeting of a DNA vaccine encoded protein for degradation via the proteasome is attempted since it may enhance the immunogenicity of the vaccine. We have fused HIV-1 reverse transcriptase (RT) to mouse ornithine decarboxylase (ODC), a protein rapidly degraded by proteasome in an ubiquitine-independent fashion, to enhance the introduction of RT into the MHC class I pathway. We also designed a fusion of RT with two short signals from the C-terminus of ODC (ODCsig) representing a minimal proteasome-targeting moiety of ODC (PEST signal). Fusion to ODC or ODC signal domain led to a marked enhancement of RT degradation. Plasmids encoding RT-ODC and RT-ODCsig chimera were used to immunize BALB/c mice. The administration of the plasmids was not associated with autoimmune disease. Moreover, mice receiving RT-ODCsig gene mounted a mixed Th1/Th2 response characterized by the in vitro secretion of IFN-gamma, IL-2, TNF-alpha, IL-4, and IL-10 upon stimulation of splenocytes with RT protein or RT derived peptides. Serum titers of 10(2) to 10(3) were observed in more than 50% of animals in that group, whereas fewer animals mounted an anti-RT response in the RT-ODC gene immunized group. Chimeras of the type described here can, therefore, be used in vaccinations aiming to induce HIV-1 RT-specific immune response.
authors.affiliation: WA Engelhardt Institute of Molecular Biology, Moscow, Russia.
authors.forename: Elizaveta S
authors.initials: ES
authors.lastname: Starodubova
authors.forename: Andreas
authors.initials: A
authors.lastname: Boberg
authors.forename: Marina
authors.initials: M
authors.lastname: Litvina
authors.forename: Alexey
authors.initials: A
authors.lastname: Morozov
authors.forename: Natalia V
authors.initials: NV
authors.lastname: Petrakova
authors.forename: Andrey
authors.initials: A
authors.lastname: Timofeev
authors.forename: Oleg
authors.initials: O
authors.lastname: Latyshev
authors.forename: Vera
authors.initials: V
authors.lastname: Tunitskaya
authors.forename: Britta
authors.initials: B
authors.lastname: Wahren
authors.forename: Maria G
authors.initials: MG
authors.lastname: Isaguliants
authors.forename: Vadim L
authors.initials: VL
authors.lastname: Karpov
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D000818:Animals; D002460:Cell Line; D016207:Cytokines / Q000378:metabolism; D005260:Female; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D054303:HIV Reverse Transcriptase / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D015497:HIV-1 / Q000201:enzymology / Q000276:immunology; D006801:Humans; D007114:Immunization; D051379:Mice; D008807:Mice, Inbred BALB C; D009955:Ornithine Decarboxylase / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D010957:Plasmids / Q000235:genetics; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D018417:Th1 Cells / Q000276:immunology*; D018418:Th2 Cells / Q000276:immunology*; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D016207:Cytokines; D011993:Recombinant Fusion Proteins; D019444:Vaccines, DNA; D054303:HIV Reverse Transcriptase; D046988:Proteasome Endopeptidase Complex; D009955:Ornithine Decarboxylase